Search Results
Dec 08, 2025, 03:00 ET AGIBOT Announces the Rollout of Its 5,000th Mass-Produced Humanoid Robot
production with 1,742 units, the fully intelligent and agile half-size robot AGIBOT X-Series has reached 1,846 units, and the task-optimized AGIBOT G-Series, designed for complex operations in manufacturing, logistics, and services, has reached 1,412 units.AGIBOT's robots are currently deployed in
More news about: Agibot
Dec 08, 2025, 02:56 ET Repurchase of Truecaller B shares in week 49, 2025
Dec. 8, 2025 /PRNewswire/ -- During week 49, 1-5 December 2025, Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 500,000 own B shares (ISIN: SE0016787071), corresponding to 0.14% of outstanding capital. Since the start of
More news about: Truecaller AB
Dec 08, 2025, 02:00 ET GOLD ROYALTY TO ACQUIRE PRODUCING PEDRA BRANCA GOLD AND COPPER ROYALTY
Mt at 1.68% copper and 0.47 g/t gold and indicated mineral resources of 12 Mt at 1.41% copper and 0.40 g/t gold, utilizing a cut-off based on an NSR value of $78.73/t. It also disclosed estimated proven mineral reserves at Pedra Branca of 1.3 Mt at 1.8% copper and 0.48 g/t gold and probable mineral reserves
More news about: Gold Royalty Corp.
Dec 08, 2025, 01:36 ET GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D
More news about: GC Biopharma
Dec 08, 2025, 01:12 ET JETOUR T2 Served as Official Vehicle for G20 South Africa 2025
JOHANNESBURG, Dec. 8, 2025 /PRNewswire/ -- The G20 South Africa 2025 was held in Johannesburg on November 22–23, marking the first time G20 took place in Africa. The JETOUR T2 debuted as the official vehicle for the summit.
More news about: Jetour
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3 for the treatment of relapsed or refractory multiple myeloma (R/R MM),
More news about: Innovent Biologics
Dec 07, 2025, 20:00 ET Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others
https://www.ghitfund.org/enAppendix: Project DetailsID: G2025-125
More news about: GHIT Fund
Dec 07, 2025, 20:00 ET Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others
https://www.ghitfund.org/enAppendix: Project DetailsID: G2025-125
More news about: GHIT Fund
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
M.D., professor, hematologist-oncologist, and Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. "BRUIN CLL-314 is the first randomized study to compare covalent and non-covalent BTK
More news about: Eli Lilly and Company
Dec 07, 2025, 09:30 ET Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
patients. The median time to onset of RBC-TI was 1.9 months and the median duration of RBC-TI was 22.9 weeks. Peak hemoglobin increases of 2.9 to 6.1 g/dL compared to baseline occurred in patients achieving RBC-TI.Of the 6 patients achieving RBC-TI, 5 had received an HMA.At doses ≥500
More news about: Rigel Pharmaceuticals, Inc.
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
treatment of advanced NSCLC adult patients harboring KRAS G12C mutation who have received at least one systemic therapy. The NRDL inclusion of Dupert®(fulzerasib) will provide a novel targeted therapy benefiting NSCLC patients harboring KRAS G12C mutation.DOVBLERON® (taletrectinib)DOVBLERON®
More news about: Innovent Biologics
Dec 06, 2025, 16:41 ET Resource Growth Programs Gain Momentum as Gold Holds Above $4,200
Northwestern Ontario. The Fork Deposit currently contains an Indicated mineral resource of 20,900 ounces grading 5.3 g/t gold with an additional Inferred resource of 49,500 ounces grading 5.2 g/t gold, with infill drilling focused on a shallow, high-grade, low-plunging zone of gold mineralization defined
More news about: Equity Insider
Dec 06, 2025, 07:15 ET Studies Highlight Innovative Approaches to Improving Patient Care and Outcomes
level improved from 10.7 to 11.8 g/dL. Patients whose hemoglobin level was 12 g/dL at study entry (above the cutoff of 11 g/dL to be considered anemic according to current guidelines from the American College of Obstetricians and Gynecologists) saw an increase to 12.8 g/dL. "These findings suggest reassessing
More news about: American Society of Hematology
Dec 06, 2025, 07:00 ET Research Reveals Avenues for Informing and Improving Sickle Cell Care
evaluated for the primary endpoint of transfusion independence for 12 consecutive months, meaning that they maintained a weighted average hemoglobin of 9 g/dL or higher without a red blood cell infusion. All six met this endpoint. In addition, participants showed increases in hemoglobin and fetal hemoglobin
More news about: American Society of Hematology
Dec 05, 2025, 19:12 ET DXCM SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against DexCom, Inc. (DXCM)
and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 continuous glucose monitoring systems that were unauthorized by the FDA; (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users
More news about: Kessler Topaz Meltzer & Check, LLP
Dec 05, 2025, 18:27 ET DXCM Deadline: DXCM Investors with Losses in Excess of $100K Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
that: (1) DexCom had made material design changes to the G6 and G7 continuous glucose monitoring ("CGM") systems that were unauthorized by the U.S. Food and Drug Administration (the "FDA"); (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a
More news about: THE ROSEN LAW FIRM, P. A.
Dec 05, 2025, 17:09 ET TROIS LÉGENDES. DEUX MARQUES PHARES. UN SHAKER EMBLÉMATIQUE.
https://mma.prnewswire.com/media/2839531/STILL_G_I_N_Logo_Logo_Logo_HexClad.jpgPhoto -
More news about: HexClad
Dec 05, 2025, 17:04 ET DREI LEGENDE. ZWEI STARKE MARKEN. EIN KULTIGER SHAKER.
https://mma.prnewswire.com/media/2839531/STILL_G_I_N_Logo_Logo_Logo_HexClad.jpgFoto -
More news about: HexClad
Dec 05, 2025, 16:56 ET TRES LEYENDAS. DOS MARCAS IMPONENTES. UNA COCTELERA ICÓNICA.
https://mma.prnewswire.com/media/2839531/STILL_G_I_N_Logo_Logo_Logo_HexClad.jpgFoto -
More news about: HexClad
Dec 05, 2025, 16:20 ET Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124.4 Lieblich A, Henne C, Mariappan P, Geiges G, Pöhlmann J, Pollock RF. The management of non–muscle-invasive bladder cancer: a comparison of European and UK guidelines. J Clin Urol. 2018;11(2):144-148.5
More news about: Johnson & Johnson
Dec 05, 2025, 15:30 ET Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025 - DXCM
DexCom had made material design changes to The Company's glucose monitoring products, the G6 and G7, unauthorized by the U.S. Food and Drug Administration; (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying
More news about: Levi & Korsinsky, LLP
Dec 05, 2025, 14:36 ET OtterBox Launches Frē Series Waterproof Phone Case for iPhone 17 Devices
and sealed port covers, so your device is safeguarded from dust, dirt, and impact. Engineered to withstand drops five times the military standard (MIL-STD-810G 516.6), Frē ensures your iPhone stays protected through life's toughest moments.Optimized for seamless integration for everyday use, Frē
More news about: OtterBox
Dec 05, 2025, 12:47 ET Ringling Bros. and Barnum & Bailey® Collaborates with Country Teen Sensation Maddox Batson on the First-Ever Music Artist Integration in the Brand's 150 Year History with an Exclusive In-Show Remix for The Greatest Show On Earth®
multimedia:https://www.prnewswire.com/news-releases/ringling-bros-and-barnum--bailey-collaborates-with-country-teen-sensation-maddox-batson-on-the-first-ever-music-artist-integration-in-the-brands-150-year-history-with-an-exclusive-in-show-remix-for-the-greatest-show-on-earth-302634281.htmlSOURCE
More news about: Ringling Bros. and Barnum & Bailey®
Dec 05, 2025, 12:46 ET Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025
the US, European Union, and other countries globally, and for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the United States. It is under regulatory review for C3G and primary IC-MPGN in the European Union and other countries globally.About
More news about: Swedish Orphan Biovitrum AB
Dec 05, 2025, 12:00 ET Synopsys, Inc. (SNPS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
SYNOPSYS, INC. (SNPS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 30, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at
More news about: Law Offices of Howard G. Smith